https://charts.traderzeitung.de/phases/US51654W1018 string(1415) "{"isin":"US51654W1018","name":"Lantern Pharma Inc","stock_id_xnas":13424544,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.495,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.44,"close_at":"2026-09-22 15:28:00","complete":true,"perf_pct":-3.6789},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.36,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-5.5556},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.38,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":1.4706},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Lantern Pharma Aktie News & Nachrichten

[WKN: A2P5NM | Symbol: LTRN]

Realtimekurs

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Lantern Pharma gefunden werden.

Lantern Pharma Nachrichtenticker öffnen

MT Newswires 28.07.2026 14:37 Uhr

Lantern Pharma gibt bekannt, dass die Phase-1b/2-Studie zu Zirdafulven bei Blasenkrebs von der Europäischen Arzneimittel-Agentur genehmigt wurde

08:35 AM EDT, 28.07.2026 (MT Newswires) -- Lantern Pharma (LTRN) teilte am Dienstag mit, dass die klinische Phase-1b/2-Studie mit LP-184 (zirdafulven)

MT Newswires 23.07.2026 14:58 Uhr

Lantern Pharma erhält US-Patentgenehmigung für Krebsmedikament LP-184

08:57 AM EDT, 23.07.2026 (MT Newswires) -- Lantern Pharma (LTRN) teilte am Donnerstag mit, dass das Unternehmen vom US-amerikanischen Patent- und Mark

MT Newswires 02.06.2026 14:51 Uhr

Lantern Pharma sagt, längere LP-300-Behandlung half Lungenkrebspatienten in Phase-2-Studie

08:50 AM EDT, 06/02/2026 (MT Newswires) -- Lantern Pharma (LTRN) teilte am Dienstag mit, dass Daten aus ihrer Phase-2-HARMONIC-Studie zur Bewertung vo